Skip to main content

Insight Molecular Diagnostics Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

IMDX$2.50+0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

For the quarterly period ended June 30, 2025

Page
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS2
PART I - FINANCIAL INFORMATION3
Item 1. Financial Statements3
CONDENSED CONSOLIDATED BALANCE SHEETS3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS4
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS5
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY6
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS8
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations43
Item 3. Quantitative and Qualitative Disclosures about Market Risk55
Item 4. Controls and Procedures55
PART II - OTHER INFORMATION56
Item 1. Legal Proceedings56
Item 1A. Risk Factors56
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds57
Item 3. Defaults Upon Senior Securities58
Item 4. Mine Safety Disclosures58
Item 5. Other Information58
Item 6. Exhibits59
SIGNATURES60
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.